Search the Newsreel

Exelixis, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:EXEL) 2026-08-06

Exelixis, Inc. published its Q2 2026 earnings call presentation. The company reported EPS of $0.91, beating estimates by $0.02, but revenue of $628.69M missed expectations by $7.46M, despite a 10.63% year-over-year increase. The slide deck provides detailed information discussed during the earnings call.

EXEL Tops Q2 Earnings Estimates, Misses on Sales, Lowers '26 View

Exelixis, Inc. (EXEL) reported mixed results for Q2 2026, beating earnings estimates with 82 cents EPS but missing revenue forecasts at $628.7 million. The company lowered its full-year 2026 revenue guidance due to a slower-than-expected ramp-up of its neuroendocrine tumor indication for Cabometyx. Despite …

Q2 2026 Exelon Corp Earnings Call Transcript

Exelon Corp (EXC) reported Q2 2026 adjusted operating earnings of $0.43 per share, meeting expectations, and reaffirmed its full-year guidance. The company demonstrated strong operational reliability, advanced a significant battery storage project in New Jersey, and implemented Transmission Security Agreements to manage speculative data …

Exelon Corporation $EXC Stake Reduced by Janus Henderson Group PLC

Janus Henderson Group PLC reduced its stake in Exelon Corporation (NASDAQ:EXC) by 36% in the first quarter, selling 98,894 shares and retaining 175,992 shares valued at $8.6 million. Despite this reduction, institutional investors collectively own 80.92% of Exelon. Analysts currently maintain a consensus "Hold" …

Zacks Research Predicts Exelixis' Q3 Earnings (NASDAQ:EXEL)

Exelixis (EXEL) Stock Drops As Guidance Cut Clouds Profit Strength

What Exelon Corporation’s Q2 Earnings Call Revealed About the Next PJM Auction

Exelixis Inc (EXEL) (Q2 2026) Earnings Call Highlights: Strong Cabozantinib Growth Offsets NET ...

This article first appeared on GuruFocus. Total Revenues: Approximately $629 million for Q2 2026. Cabozantinib Franchise Net Product Revenues (US): $573 million, up approximately 10% year-over-year. Global Cabozantinib Franchise Net Product Revenues (Exelixis and partners): $806 million, up approximately 13% year-over-year. CABOMETYX Net Product …

Exelixis (EXEL) Tops Q2 Earnings Estimates

Exelixis (EXEL) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.86 per share. This compares to earnings of $0.75 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …

Exelixis Q2 2026 earnings: Cabozantinib growth lifts revenue and EPS

Exelixis reported strong Q2 2026 earnings, with revenue reaching $628.7 million, a 10.6% increase year-over-year, and diluted EPS rising to $0.82. This growth was primarily driven by higher sales volume of cabozantinib, though the company lowered its full-year revenue outlook. Exelixis continues to invest …

Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Exelixis reported strong second-quarter 2026 financial results, with total revenues reaching $628.7 million and GAAP diluted EPS of $0.82. The company highlighted the continued growth of its cabozantinib franchise and significant progress in its zanzalintinib development program, including ongoing regulatory review for metastatic colorectal …

Transcript : Exelixis, Inc., Q2 2026 Earnings Call, Aug 05, 2026

This article is a transcript of Exelixis, Inc.'s Q2 2026 Earnings Call held on August 5, 2026. During the call, Exelixis updated its fiscal 2026 revenue guidance to $2.50B-$2.55B, lower than FactSet's estimate of $2.60B. The company also reported Q2 revenue of $628.7M and …

Earnings Flash (EXEL) Exelixis, Inc. Reports Q2 Revenue $628.7M, vs. FactSet Est of $636.4M

Exelixis, Inc. (EXEL) reported its Q2 revenue at $628.7 million, falling short of the FactSet estimate of $636.4 million. The company also updated its fiscal year 2026 revenue guidance to a range of $2.50 billion to $2.55 billion, which is below the FactSet estimate …

Exelixis earnings on deck as generic threat looms

Exelixis Inc. is set to report second-quarter earnings, facing scrutiny over its flagship cancer drug, Cabometyx, due to an escalating patent dispute and the emergence of a generic alternative. Investors are also keenly watching the commercialization prospects for its next-generation pipeline drug, zanzalintinib, and …

Royal Bank of Canada Grows Stock Holdings in Exelixis, Inc. $EXEL

Royal Bank of Canada increased its holdings in Exelixis, Inc. by 24.6% in the first quarter, now owning 694,131 shares valued at approximately $29.8 million. This increase comes as Exelixis reported strong quarterly earnings, beating analyst estimates, with revenue up 10% year-over-year. Despite recent …

Rexel: Statement relating to the total number of shares and voting rights as of July 31, 2026

Rexel Développement SAS Rexel: Statement relating to the total number of shares and voting rights pursuant to Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Rules of the French Autorité des marchés financiers Date Number of shares Number …

Exelixis (EXEL) Stock Still Looks Cheap On Earnings While Returns Look Rich

Exelixis (EXEL) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

How Exelon’s Q2 Results, Dividend and Grid Investments Could Impact Exelon (EXC) Investors

Exelixis, Inc. $EXEL Shares Sold by Private Client Services LLC

Private Client Services LLC reduced its stake in Exelixis, Inc. (NASDAQ:EXEL) by 40.9% in the second quarter, selling 19,576 shares. Despite this, Exelixis reported strong quarterly earnings of $0.87 per share, surpassing estimates, with revenue increasing 10% year over year to $610.81 million. The …

Exelon Secures More Than $1 Billion in Customer Protections Through Pioneering Transmission Security Agreements

A Cornerstone of The Exelon Promise, Transmission Security Agreements Shield Families and Small Businesses from Unfair Cost Shifts, Including Those Driven by Data Centers, Amid Power Generation Shortfalls CHICAGO, August 04, 2026--(BUSINESS WIRE)--Exelon has secured more than $1 billion in customer protections through pioneering …

Exelon Agreements Require Data Centers to Cover Projected Grid Costs

Exelon has secured over $1 billion in customer protections through Transmission Security Agreements (TSAs), which mandate that large new energy users, including data centers, cover their projected transmission service costs. This initiative is part of the "Exelon Promise" to shield families and small businesses …

Exelon (EXC) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, July 30, 2026, at 10 a.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Ryan Brown President and Chief Executive Officer - Calvin Butler Chief Financial Officer - Jeanne Jones President and Chief Executive Officer of …

Exelon Corporation Just Missed EPS By 13%: Here's What Analysts Think Will Happen Next

Exelon Weeds Out Data Center Pipeline

Exelon has significantly reduced its estimates for data center growth within its service areas, culling speculative projects to focus on durable growth. The utility now anticipates 36 gigawatts of data center work, down from over 60 GW three months prior, with 11 GW in …

Exelixis Inc expected to post earnings of 79 cents a share - Earnings Preview

Exelixis Inc. is anticipated to report earnings of 79 cents per share. This information is provided as an earnings preview from Reuters, accessible via TradingView. The full article is available with unlimited access on TradingView.

Exelon (EXC) Could Be a Great Choice

All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments. While cash flow can …

Exelixis stock rating maintained at Market Outperform by Citizens

Citizens has maintained a Market Outperform rating and a $55.00 price target for Exelixis (NASDAQ:EXEL), noting that the stock appears undervalued according to InvestingPro analysis. The article also discusses the ongoing patent dispute between Exelixis and Handa Oncology regarding a new cabozantinib formulation and …

Exelon Corp reports results for the quarter ended June 30 - Earnings Summary

Exelon Corp has released its earnings summary for the quarter that ended on June 30. The full article, available through Reuters on TradingView, requires unlimited access to view.

Exelon (EXC) Reaffirmed Guidance, Is The Stock Fairly Valued?

HEARTLAND MID CAP VALUE FUND's Exelon Corp(EXC) Holding History

This article details HEARTLAND MID CAP VALUE FUND's historical holdings in Exelon Corp (EXC). As of March 31, 2026, the fund held 363,489 shares valued at $17.82 million, representing 3.89% of its portfolio. The fund has made multiple purchases and sales of EXC since …

Exelon Corp Lobbyists, 2011

This article from OpenSecrets details the lobbyists employed by Exelon Corp in 2011. It provides a comprehensive list of 64 lobbyists, noting that 51 (79.7%) had prior federal government experience, including 3 former members of Congress. The article also breaks down which firms employed …

Exelon (EXC) Stock May Be Undervalued Following Data Center Load Reset

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Exelon has delivered a 61.0% total return over the past five years. However, the …

Does Steady Q2 Results And New Grid Projects Change The Bull Case For Exelon (EXC)?

Exelon Corporation recently reported past second-quarter 2026 results, with revenue rising to US$5,967 million from US$5,427 million a year earlier, while net income and earnings per share were essentially flat, and the board declared a regular quarterly dividend of US$0.42 per share payable in …

Exelixis, Inc. Revenue Breakdown – NASDAQ:EXEL

Exelixis, Inc. (EXEL) generated $2.32 billion in revenue last year, primarily from its "Medicines for Difficult-to-treat Cancers" segment. This represents an increase from $2.17 billion in the previous year. The United States was the largest contributor to revenue, accounting for $2.14 billion.

EXC5508234 Bond Profile — Key Metrics

This article provides a detailed profile of the Exelon Corporation 2.75% 15-MAR-2027 bond (EXC5508234), outlining key metrics such as its issue date, maturity date, outstanding amount, face value, and coupon rate. It also describes Exelon Corp. as a utility services holding company with several …